Results 31 to 40 of about 21,829 (156)

Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization [PDF]

, 2020
Objectives: The aim of this study was to evaluate the incidence of ceftazidime/avibactam resistance among Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-Kp) strains isolated from patients with bloodstream infection.
Ambretti S., Viale P. L., Gaibani P., Campoli C., Re M. C.   +4 more
core   +1 more source

A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring bla_KPC-14 Isolated in New York City

mSphere, 2020
Ceftazidime-avibactam is a potent antibiotic combination against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae. Here, we describe a unique ceftazidime-avibactam-resistant and carbapenem-susceptible K.
Siqiang Niu, Kalyan D. Chavda, Jie Wei, Chunhong Zou, Steven H. Marshall, Puneet Dhawan, Deqiang Wang, Robert A. Bonomo, Barry N. Kreiswirth, Liang Chen   +9 more
doaj   +3 more sources

Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: Experience from a national registry study

, 2021
Background: Infections caused by KPC-producing Klebsiella pneumoniae (Kp) are associated with high mortality. Therefore, new treatment options are urgently required.
Giamarellou, H., Symbardi, S., Filiou, E., Adamis, G., Basoulis, D., Mouloudi, E., Karaiskos, I., ikaraiskos@hygeia.gr, Akinosoglou, K., Gkoufa, A., Masgala, A., Petraki, M., Stefos, A., Chrysos, G., Daikos, G.L., Galani, L., Papadimitriou, E., Poulakou, G., Routsi, C., Galani, I., Arvaniti, K., Karaiskos I., ikaraiskos@hygeia.gr, Daikos G.L., Gkoufa A., Adamis G., Stefos A., Symbardi S., Chrysos G., Filiou E., Basoulis D., Mouloudi E., Galani L., Akinosoglou K., Arvaniti K., Masgala A., Petraki M., Papadimitriou E., Galani I., Poulakou G., Routsi C., Giamarellou H.   +20 more
core   +2 more sources

Outbreak of Klebsiella pneumoniae ST11 Resistant To Ceftazidime-Avibactam Producing KPC-31 and the Novel Variant KPC-115 during COVID-19 Pandemic in Argentina

Microbiology Spectrum, 2022
We describe an outbreak of Klebsiella pneumoniae sequence type 11 (ST11) producing KPC variants resistant to ceftazidime-avibactam. Six patients hospitalized in the intensive care unit (mostly due to critical COVID pneumonia) presented infection or ...
Federico Nicola, Daniela Cejas, Francisco González-Espinosa, Silvia Relloso, Fabián Herrera, Pablo Bonvehí, Jorgelina Smayevsky, Roque Figueroa-Espinosa, Gabriel Gutkind, Marcela Radice   +9 more
doaj   +1 more source

Use of Ceftazidime-Avibactam for Suspected or Confirmed Carbapenem-Resistant Organisms in Children: A Retrospective Study

, 2023
Haiyang Meng,1,2 Yongmei Zhao,1,2 Qi An,1,2 Baoling Zhu,3 Zhe Cao,4 Jingli Lu1,2 1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 2Henan Key Laboratory of Precision Clinical Pharmacy ...
An Q, Cao Z, Lu J, Zhu B, Meng H, Zhao Y
core  

In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment [PDF]

, 2018
Objectives: KPC-producing Klebsiella pneumoniae (KPC-Kp) represent a serious problem worldwide. Herein, we describe the evolution of ceftazidime/avibactam resistance by sequencing longitudinal clinical isolates from a patient with KPC-Kp bloodstream ...
Andrea Berlingeri, Sara Tedeschi, Paolo Gaibani, Giannella, Maddalena, Maddalena Giannella, Silvia Lidia Volpe, Tedeschi, Sara, Bartoletti, Michele, Erika Scaltriti, Berlingeri, Andrea, Lewis, Russell E., Michele Bartoletti, Caterina Campoli, Simone Ambretti, Gaibani, Paolo, Scaltriti, Erika, Campoli, Caterina, Francesco Cristini, Pongolini, Stefano, Volpe, Silvia Lidia, Cristini, Francesco, Ambretti, Simone, Stefano Pongolini, Russell E Lewis   +23 more
core   +1 more source

Ceftazidime/Avibactam: Who Says You Can’t Teach an Old Drug New Tricks?

Journal of Pharmacy & Pharmaceutical Sciences, 2016
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique,
Katie E. Barber, Jessica K. Ortwine, Ronda L Akins   +2 more
doaj   +1 more source

Multiple Novel Ceftazidime-Avibactam-Resistant Variants of blaKPC-2-Positive Klebsiella pneumoniae in Two Patients

Microbiology Spectrum, 2022
As the first-line antimicrobial agent for the infection caused by carbapenem-resistant Enterobacterales, ceftazidime-avibactam develops drug resistance during its ever-growing clinical use.
Qingyu Shi, Renru Han, Yan Guo, Yang Yang, Shi Wu, Li Ding, Rong Zhang, Dandan Yin, Fupin Hu   +8 more
doaj   +1 more source

Interpretation of Key Updates in the 36th Edition of Clinical and Laboratory Standards Institute M100 Standard

iLABMED, EarlyView.
ABSTRACT The Clinical and Laboratory Standards Institute M100 document serves as a cornerstone standard for clinical microbiology laboratories in China. Maintaining the scientific rigor of its predecessors, the 36th edition incorporates updated epidemiological cutoff values, pharmacokinetic/pharmacodynamic data, and clinical efficacy evidence to revise
Kanghong Xu, Qi Wang, Hui Wang
wiley   +1 more source

Boronic Acid Inhibitors of β‐Lactamases: A Promising Strategy Against Antimicrobial Resistance

Medicinal Research Reviews, EarlyView.
ABSTRACT The rise of antimicrobial resistance (AMR) poses a critical threat to global health, mostly due to the proliferation of β‐lactamases, a class of enzymes responsible for the inactivation of β‐lactam antibiotics. Among the most promising strategies to restore β‐lactam efficacy is the use of β‐lactamase inhibitors (BLIs), with boronic acid ...
Nicolò Santi, Federico Corsini, Robert A. Bonomo, Emilia Caselli, Fabio Prati   +4 more
wiley   +1 more source